Table 4 Encounter-level data on the explorative process outcomes including documentation of accurate risk assessment and clinicians’ recommended surveillance intervals by site. N refers to the number of encounters evaluated at each site and phase
Overall (combining all risk levels) | |||
|---|---|---|---|
Site 1 | |||
Pre-implementation (N = 66) | Integration (N = 44) | Evaluation (N = 45) | |
Accurate Documentation | 29 [43.9%] | 20 [45.4%] | 24 [53.3%] |
Recommendation for guideline-concordant surveillance interval | 54 [81.8%] | 36 [81.8%] | 39 [86.7%] |
Site 2 | |||
Pre-implementation (N = 45) | Integration (N = 50) | Evaluation (N = 55) | |
Accurate Documentation | 12 [26.7%] | 25 [50.0%] | 44 [80.0%] |
Recommendation for guideline-concordant surveillance interval | 36 [80.0%] | 46 [92.0%] | 50 [90.9%] |
Site 3 | |||
Pre-implementation (N = 84) | Integration (N = 58) | Evaluation (N = 121) | |
Accurate Documentation | 60 [71.4%] | 33 [56.9%] | 90 [74.4%] |
Recommendation for guideline-concordant surveillance interval | 76 [90.5%] | 48 [82.7%] | 102 [84.3%] |
Site 4 | |||
Pre-implementation (N = 53) | Integration (N = 61) | Evaluation (N = 73) | |
Accurate Documentation | 44 [83.0%] | 51 [83.6%] | 66 [90.4%] |
Recommendation for guideline-concordant surveillance interval | 49 [92.4%] | 54 [88.5%] | 70 [95.9%] |